Formycon CEO Stefan Glombitza highlighted their strong position in the legal dispute, alongside major players like Amgen. They expect a favorable outcome despite market share fluctuations and are confident in launching FYB202 with Fresenius Kabi in the US by February 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
